The INOmax® (nitric oxide) gas, for inhalation,
cylinder benefits

100% tested and inspected 100% tested and inspected

Be confident in our drug purity*

  • INOmax drug is produced in our FDA-regulated Port Allen, Louisiana, pharmaceutical manufacturing facility1
  • 100% of INOmax cylinders are tested and inspected to ensure quality and purity meet specifications2
  • Testing, verification, and distribution specifications ensure you are delivering INOmax through your INOmax device2
*Purity requirement is ±5% of INOmax cylinder concentration.2

Innovative cylinder-delivery technology

Our next-generation INOmax EVOLVE™ DS delivery system uses 0.4-L INOmax mini-cylinders that weigh 1.43 lb.3

Ergonomic mini-cylinders5,6 Ergonomic mini-cylinders5,6

Used INOmax cylinders are returned to Mallinckrodt, where they are reprocessed and refilled5

greater than three-hundred thousand

cylinders produced in the last 3 years,*
with a maximum of >121,000 cylinders produced in 2021.6

*Data from 2020 to 2022.

The long-standing legacy
of INOmax

  • In 1992, nitric oxide was named Molecule of the Year11
  • In 1998, 3 scientists won the Nobel Prize in Physiology and Medicine for their discoveries concerning the role of nitric oxide as a signaling molecule12
  • Inhaled nitric oxide (iNO) was the first selective pulmonary vasodilator and was FDA-approved as INOmax in 199910,13
  • INOmax continues to be the market leader* of iNO delivery for HRF over 20 years later14
*Based on December 2022 market share data.

See how INOmax works

Watch this video to see INOmax’s mechanism of action

View transcript
Play Video Button

Learn about the safety and efficacy of INOmax

See the data

Learn about dosing, administration, and weaning required for INOmax

Learn more

Access additional resources about INOmax

View resources

INDICATION

INOmax is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

IMPORTANT SAFETY INFORMATION

  • INOmax® (nitric oxide) gas, for inhalation, is contraindicated in the treatment of neonates dependent on right-to-left shunting of blood.
  • Abrupt discontinuation of INOmax may lead to increasing pulmonary artery pressure and worsening oxygenation.
  • Methemoglobinemia and NO2 levels are dose dependent. Nitric oxide donor compounds may have an additive effect with INOmax on the risk of developing methemoglobinemia. Nitrogen dioxide may cause airway inflammation and damage to lung tissues.
  • In patients with pre-existing left ventricular dysfunction, INOmax may increase pulmonary capillary wedge pressure leading to pulmonary edema.
  • Monitor for PaO2, inspired NO2, and methemoglobin during INOmax administration.
  • INOmax must be administered using a calibrated FDA-cleared Nitric Oxide Delivery System.

Please see Full Prescribing Information.

References: 1. INOmax. Label. INO Therapeutics LLC. DailyMed; 2023. Updated April 12, 2023. Accessed May 11, 2023. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=762b51be-1893-4cd1-9511-e645fc420d3a 2. Data on File – Ref-06554. Mallinckrodt Pharmaceuticals. 3. INOmax EVOLVE™ DS Operation Manual. Madison, WI: Mallinckrodt Pharmaceuticals; 2024. 4. Manual Handling in Occupational Tasks. Kodak’s Ergonomic Design for People at Work. 2003;(9780471418634):511-563. 5. Data on File – Ref-05971. Mallinckrodt Pharmaceuticals. 6. Data on File – Ref-06556. Mallinckrodt Pharmaceuticals. 7. Williams LJ, Shaffer TH, Greenspan JS. Inhaled nitric oxide therapy in the near-term or term neonate with hypoxic respiratory failure. Neonatal Netw. 2004;23(1):5-13. doi:10.1891/0730-0832.23.1.5 8. Lakshminrusimha S, Saugstad OD. The fetal circulation, pathophysiology of hypoxemic respiratory failure and pulmonary hypertension in neonates, and the role of oxygen therapy. J Perinatol. 2016;36(suppl 2):S3-S11. doi:10.1038/jp.2016.43 9. Lakshminrusimha S. The pulmonary circulation in neonatal respiratory failure. Clin Perinatol. 2012;39(3):655-683. doi:10.1016/j.clp.2012.06.006 10. INOmax. Package insert. Mallinckrodt Pharmaceuticals. 11. Koshland DE Jr. The molecule of the year. Science. 1992;258(5090):1861. doi:10.1126/science.1470903 12. SoRelle R. Nobel prize awarded to scientists for nitric oxide discoveries. Circulation. 1998;98(22):2365-2366. doi:10.1161/01.cir.98.22.2365 13. Ichinose F, Roberts JD Jr, Zapol WM. Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential. Circulation. 2004;109(25):3106-3111. doi:10.1161/01.CIR.0000134595.80170.62 14. Data on File – Ref-06557. Mallinckrodt Pharmaceuticals.

Live help is available 24/7/365

Call 877-566-9466

Quick Links

INOmax DSIR® Plus Virtual Training Simulator Resource Library FLEXtraNet® Log-in INOmax DSIR® Plus Operation Manual INOmax DSIR® Plus MRI Operation Manual

Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners.

This website may identify third-party organizations and provide links to third-party websites or other third-party information (third-party content). The third-party content is meant for informational purposes only, is not endorsed by or under the control of Mallinckrodt, and is not meant to replace a physician’s medical advice. Mallinckrodt has no responsibility or liability for and makes no representations or warranties whatsoever about any third-party content. All trademarks, service marks, and logos appearing on this website are the property of their respective owners. Any rights not expressly granted herein are reserved.

© 2024 Mallinckrodt. All rights reserved. US-2400124 03/24

By viewing this site you agree to our Terms of Use. The product information provided in this site is intended only for residents of the United States. The product discussed herein may have different product labeling in different countries.

INDICATION

INOmax is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

INDICATION

INOmax is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

IMPORTANT SAFETY INFORMATION

  • INOmax® (nitric oxide) gas, for inhalation, is contraindicated in the treatment of neonates dependent on right-to-left shunting of blood.
  • Abrupt discontinuation of INOmax may lead to increasing pulmonary artery pressure and worsening oxygenation.
  • Methemoglobinemia and NO2 levels are dose dependent. Nitric oxide donor compounds may have an additive effect with INOmax on the risk of developing methemoglobinemia. Nitrogen dioxide may cause airway inflammation and damage to lung tissues.
  • In patients with pre-existing left ventricular dysfunction, INOmax may increase pulmonary capillary wedge pressure leading to pulmonary edema.
  • Monitor for PaO2, inspired NO2, and methemoglobin during INOmax administration.
  • INOmax must be administered using a calibrated FDA-cleared Nitric Oxide Delivery System.

Please see Full Prescribing Information.